









Markets
/
Stocks
/
nasdaq-cgc
/

Canopy Growth Corp

CGC



View Detailed Chart

1.415USD

+0.095+7.20%

Market hours （ET）Quotes delayed by 15 min

470.32MMarket Cap

LossP/E TTM



Canopy Growth Corp

1.415

+0.095+7.20%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+7.20%

5 Days

-14.76%

1 Month

+27.48%

6 Months

+14.11%

Year to Date

-48.36%

1 Year

-50.00%

View Detailed Chart

TradingKey Stock Score of Canopy Growth Corp

Currency: USD Updated: 2025-12-22

Key Insights

Canopy Growth Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 87/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 3.65.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Canopy Growth Corp's Score

Industry at a Glance

Industry Ranking

87 / 158

Overall Ranking

234 / 4578

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Hold

Current Rating

3.650

Target Price

+234.86%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Canopy Growth Corp Highlights

StrengthsRisks

Canopy Growth Corporation is a Canada-based cannabis company. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company delivers innovative products from owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. Its segments include Canada cannabis, and Storz & Bickel. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers. In addition, it serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.

Fairly Valued

The company’s latest PE is -0.69, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 38.22M shares, decreasing 0.04% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.73.

Canopy Growth Corp News

Trump Advocates CBD for Medicare Inclusion, Igniting Cannabis Stock Surge; Tilray Brands Soars 60%

TradingKey - On Monday, September 29th, Donald Trump posted a video on Truth Social endorsing the health benefits of cannabidiol (CBD) for seniors and advocating for its inclusion in Medicare coverage. This announcement sent U.S. cannabis stocks soaring.

TradingKeyTue, Sep 30

Cannabis Stocks Rally 40% After Trump Considers Drug Reclassification

TradingKey - Cannabis stocks soared after President Donald Trump announced on Monday that he is considering reclassifying cannabis to a less-dangerous drug classification, with a decision expected in the coming weeks.

TradingKeyTue, Aug 12